Riebman Jerome 4

4 · AZIYO BIOLOGICS, INC. · Filed Mar 10, 2022

Form 4

Period: 2022-03-08

Chief Medical Officer

Transactions

Award
Stock Option (Right to Buy)
2022-03-08+31,000→ 31,000 total
Exercise: $5.08Exp: 2032-03-08→ Class A Common Stock (31,000 underlying)
Exercise/Conversion
Restricted Stock Units
2022-03-08−782→ 2,343 total
→ Class A Common Stock (782 underlying)
Exercise/Conversion
Class A Common Stock
2022-03-08+782→ 5,334 total
Award
Restricted Stock Units
2022-03-08+14,758→ 14,758 total
→ Class A Common Stock (14,758 underlying)
Award
Restricted Stock Units
2022-03-08+8,700→ 8,700 total
→ Class A Common Stock (8,700 underlying)

Footnotes (7)

[F1]Restricted stock units convert into shares of Class A Common Stock on a one-for-one basis.
[F2]Includes 4,552 shares of Class A Common Stock acquired under the Company's 2020 Employee Stock Purchase Plan.
[F3]The option vests as to 25% of the shares on March 8, 2023 and in 12 equal quarterly installments thereafter, such that the option shall be fully vested and exercisable on March 8, 2026.
[F4]Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.
[F5]The restricted stock units vest if the Issuer's Class A Common Stock achieves a price per share equal to or greater than $10.00 for any period of thirty (30) consecutive trading days prior to March 8, 2024.
[F6]On March 8, 2021, the Reporting Person was granted 3,125 restricted stock units, vesting in four substantially equal annual installments beginning on March 8, 2022.
[F7]The restricted stock units vest on September 8, 2022, subject to the Reporting Person's continuous employment with the Issuer through such vesting date.

Documents

1 file